A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket. The ...

Concern about the safety of gene therapies has been thrust into the spotlight again with the news that two patients treated with Novartis' spinal muscular atrophy (SMA) treatment Zolgensma died as ...

mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at up to ...

Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments. As a result, there are now a number of ...

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured £920,000 from the British government’s Innovate UK to create a safe, effective red ...

Disc Medicine has charted a route to market for its bitopertin drug for rare disease erythropoietic protoporphyria.

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali ...

HHS Secretary Kennedy adds yet another layer of scrutiny to childhood vaccines with the re-establishment of a task force disbanded in the 1990s.

Hundreds of current and former workers at the Department of Health and Human Services (HHS) have penned a letter to Robert F Kennedy Jr, asking him to stop spreading misinformation that is ...